Masseter Changes Over Time: What Do Studies Show?

Evidence Brief Conclusion

The human evidence reviewed here does not establish that repeated exposure over many years is either harmless or inevitably damaging. Findings over twelve months are reassuring for the endpoints and exposure studied. They do not establish whether repeated exposure over many years changes bone, muscle bulk or facial balance.

The practical response is not alarm or automatic reassurance. A personal history of previous care, intervals, changing function and lower face structure should be reviewed by an appropriately qualified practitioner. The public evidence cannot determine whether further care is suitable for an individual.

Evidence At A Glance

The table keeps each measured endpoint beside the population, exposure and limits that define it.

How This Evidence Brief Was Built

This is a structured clinic evidence brief, not a formal systematic review or clinical practice guideline. The search began with the main recent human review, the later randomised trial publications, the registered trial record and Australian regulatory guidance. Each paper was checked for population, exposure, comparator, endpoint, timeframe, funding and stated limitations.

The conclusion is deliberately narrower than the papers themselves. A finding is only applied to the endpoint, people and timeframe actually studied. Where the research does not answer repeated exposure over several years, this brief says so rather than filling the gap with reassurance or speculation.

The editorial and evidence policy explains authorship, clinical review, AI assistance, corrections and conflict disclosure across the site.

What The 2024 Review Found

The 2024 Journal of Oral Rehabilitation review reported a pooled 6.34% reduction in human mandibular cortical thickness (95% confidence interval: a reduction of 2.42% to 10.25%). The largest regional estimate was at the condyle, but that subset came from only two studies. Coronoid and ramus estimates were smaller.

This is a signal to investigate, not a prediction of permanent or visible change. The human studies predominantly involved women with myofascial temporomandibular disorders, and several involved the temporalis as well as the masseter. They are not equivalent to a healthy cosmetic masseter population.

What The 2025 Density Analysis Found

The density paper first published in 2025 analysed 123 adults from trial NCT02010775 who had complete CT scans. It excluded the lowest active-dose group and participants with missing scans. Participants had one or two sessions over twelve months. CT measurements at the condyle, premolar area and ramus did not show clinically significant density changes against baseline or placebo.

This is useful evidence for the measured locations and study window. It is not an absolute bone mineral density measurement. The authors’ conclusion of no clinically significant change is not a finding that every measurement stayed unchanged, nor evidence about many cycles over several years.

What The 2026 Morphology Analysis Added

The 2026 morphology paper used the broader 187 person population from the same registered trial, which recruited adults aged 18 to 50 with marked bilateral masseter prominence. Its eligibility criteria excluded diagnosed temporomandibular disorders. It examined predefined measures including bigonial width, cortical thickness at the masseter insertion, flare angle, gonial angle and qualitative joint findings. It reported no detectable differences between active and placebo groups over twelve months.

These are group-level shape and insertion site measurements, not predictions of facial appearance. The paper did not test correlations between muscle-volume or bite-force changes and bone endpoints. It also states that effects emerging after twelve months cannot be excluded.

Why The Later Papers Are Not Independent Replication

The 2025 and 2026 publications are not two separate randomised trials. Both analyse NCT02010775. One focused on a complete-scan density subgroup. The other examined morphology in the broader trial population.

Separate publications can answer separate endpoint questions, but agreement within one trial is not the same as an independent research group reproducing the finding in a new population. That distinction affects how confidently the finding can be generalised.

Why Thickness, Density And Morphology Need Separate Answers

Cortical thickness is the width of the hard outer shell of bone. Density describes how compact the measured region appears. Morphology describes dimensions, angles and overall shape. One endpoint can remain stable while another changes.

A density paper does not negate a thickness signal, and a small pooled thickness signal does not establish a visible face shape change. The honest answer preserves each endpoint instead of compressing everything into the phrase “bone loss”.

What Lower Face Hollowing Can Mean

Some people describe a hollow, flat or gaunt lower face after extensive reduction. The masseter contributes to fullness around the jaw angle, so reduced muscle bulk can alter balance even without a demonstrated bone change.

Weight change, cheek support, natural anatomy and the amount of reduction also affect appearance. A visible hollow does not identify one cause by itself. This is why Corey assesses whether the muscle is contributing useful support before any further clinical discussion.

What The Evidence Cannot Yet Answer

The two later trial papers reviewed here describe one or two study sessions over twelve months. They do not establish a typical long term path for one person or the cumulative effect of many cycles.

If a person has already received care affecting this muscle, an assessment should record dates, prior response, function and any change in lower face balance. Public evidence cannot determine whether further care is suitable.

• The number and spacing of previous sessions are part of the history.
• The lower face should be reassessed when function or appearance changes.
• Existing muscle bulk may be contributing useful fullness or support.
• Dental or medical assessment may be more appropriate when symptoms are functional.

Risks And Symptoms That Change The Assessment

Reported and clinically discussed risks in this area include bruising, pain, temporary chewing weakness, altered smile movement, asymmetry and more lower face hollowing than intended. The relevance of each risk depends on anatomy, previous response, health history and the care received.

Dental pain, jaw clicking, restricted movement or other functional symptoms may need dental or medical assessment rather than a cosmetic pathway.

Funding And Conflicts Matter

The 2025 density paper and 2026 morphology paper report manufacturer sponsorship. Their disclosures include authors who were employees, stockholders, consultants or grant recipients. The sponsor participated in study design, research, analysis, interpretation and publication review.

That does not make the findings false. It does mean the evidence should be read with the funding context visible and should ideally be tested by independent groups using longer follow up and repeated exposure designs.

How Corey Uses This In Consultation

Corey Anderson RN looks at whether the masseter is contributing to the concern, whether existing bulk is supporting the lower face, how many previous cycles have occurred and whether more reduction still makes sense. Dental symptoms, jaw pain, clicking or functional concerns may need a different pathway.

The evidence does not create a predetermined pathway recommendation. It supports a more careful conversation about uncertainty, cumulative history, facial structure and whether the likely benefit justifies another cycle.

What Would Change This Conclusion

Confidence would improve with independent prospective studies that follow people through multiple cycles for several years, record cumulative exposure, use validated density and thickness methods, and report visible facial changes alongside imaging. Studies should also publish prespecified endpoints, loss to follow up and funding relationships.

Until that evidence exists, the conclusion remains bounded: one year randomised findings are reassuring for their measured endpoints, while long term cumulative effects remain uncertain.

Evidence Brief Revision History

Continue Through The Evidence Series

Read how Core Aesthetics clinical evidence briefs are prepared, including how endpoints, timeframes, funding and uncertainty are recorded. For anatomy, continue to masseter muscle explained. For public safety and decision context, read patient safety and regulation and how informed consent works.

The editorial and evidence policy explains how sources, conflicts, corrections and review dates are handled. Use Verify Core Aesthetics to check Corey Anderson RN independently on the Ahpra public register.